FOLLICULAR LYMPHOMA

This study tests a new combination of drugs for people with a type of slow-growing blood cancer called follicular lymphoma that has a high tumor burden. The treatment includes tazemetostat (a targeted pill) plus rituximab (an antibody) and a shortened course of bendamustine (chem…

This study tests a two-drug combination (ixazomib and rituximab) in people with slow-growing B-cell non-Hodgkin lymphoma. The goal is to see how well the drugs shrink or control the cancer. About 33 adults with different types of this lymphoma are taking part.

This early-phase study tests a personalized cancer vaccine designed to target each patient's unique tumor. 20 adults with follicular lymphoma will receive the vaccine along with pembrolizumab after standard rituximab treatment. The main goal is to see if the vaccine can be made q…

This study tests whether adding special 'veto' cells to a stem cell transplant can help donor cells grow in the body without causing severe graft-versus-host disease (GVHD). It includes 16 people aged 12-75 with various blood cancers or bone marrow failure. The veto cells are tre…

This study tests whether combining copanlisib and rituximab can slow or stop follicular lymphoma, a type of blood cancer, in people who haven't had treatment yet. About 33 participants will receive the drugs through an IV over several months. The goal is to see how many achieve a…

This study tests a combination of two drugs, mosunetuzumab and lenalidomide, in people with follicular lymphoma, a type of blood cancer. The goal is to see if the combo is safe and works better than standard treatments. About 237 adults whose cancer has returned or needs treatmen…

This study tests a combination of two drugs, mosunetuzumab and polatuzumab vedotin, in people with untreated follicular lymphoma. The drugs work together to help the immune system find and kill cancer cells. The goal is to see how many patients have their tumors completely disapp…

This study tests a combination of two drugs, tazemetostat (pills) and mosunetuzumab (injections), in 23 people with untreated follicular lymphoma. The goal is to see if the combination works better than either drug alone, while still being safe. Both drugs are already approved fo…

This study tests a drug called epcoritamab in about 78 Japanese adults with B-cell lymphoma that has come back or not responded to treatment. The goal is to find the safest dose and see if the drug can shrink tumors. The study has two parts: first, finding the right dose, then te…

This study tests a drug called MK-2140 (zilovertamab vedotin) in people with certain B-cell blood cancers that have come back or not responded to other treatments. About 189 adults with mantle cell lymphoma, Richter's transformation lymphoma, follicular lymphoma, or chronic lymph…

This study tests whether adding the drug tafasitamab to a standard two-drug combination (lenalidomide plus rituximab) helps people with relapsed or refractory follicular lymphoma or marginal zone lymphoma live longer without their cancer getting worse. About 654 adults who have a…

This study tests whether adding the drug vorinostat to standard care can lower the chance of graft-versus-host disease (GVHD) in children, teens, and young adults getting a bone marrow or blood stem cell transplant for blood cancers. About 43 participants will receive vorinostat …

This early-phase study tests a combination of two drugs, copanlisib and nivolumab, in people with certain types of blood cancer that have changed into a more aggressive form (Richter's transformation or transformed non-Hodgkin lymphoma). The goal is to find the best dose and see …

This study tests whether combining two immunotherapy drugs, glofitamab and obinutuzumab, can safely and effectively treat people newly diagnosed with follicular lymphoma or marginal zone lymphoma. The 47 participants have not had any prior lymphoma treatment. The goal is to see i…

This study looks at whether giving a pneumococcal vaccine (PCV13) before and after CAR T-cell therapy can improve the body's ability to fight off pneumococcus bacteria. It involves 26 adults with certain types of lymphoma who are scheduled for CAR T-cell treatment. The main goal …

This study compares a shorter chemotherapy regimen combined with immunotherapy to the standard full-length treatment for people with newly diagnosed, advanced follicular lymphoma that has a high tumor burden. About 605 participants will be randomly assigned to either the shortene…

This early-phase study looks at whether giving low-dose radiation before CAR T-cell therapy is practical and safe for people with B-cell lymphoma that has returned or not responded to treatment. About 33 adults will receive radiation to shrink tumors while waiting for their CAR T…

This study looks at how well the drug tazemetostat works in adults with follicular lymphoma, a slow-growing blood cancer, that has returned or not responded after at least two prior treatments. Participants take tazemetostat as prescribed by their doctor in routine care. The stud…

This study tests a combination of two drugs, epcoritamab and lenalidomide, in 29 adults with untreated follicular lymphoma, a slow-growing blood cancer that is not currently curable. The goal is to see if the pair works better than either drug alone to shrink tumors and improve r…

This study tests whether adding the experimental drug tazemetostat to a standard two-drug therapy can help people with relapsed or refractory follicular lymphoma live longer without their cancer getting worse. About 555 adults whose lymphoma has returned or no longer responds to …

This early-stage study tests a new drug called IMT-009 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goals are to find a safe dose and learn about side effects. About 67 participants will receive the drug intravenously,…

This study looked at how well and how safely the drug tazemetostat works in adults with a type of blood cancer called follicular lymphoma that has come back or not responded to previous treatments. Participants took tazemetostat pills twice daily. The study aimed to see if the dr…

This study tests an investigational drug called epcoritamab, given alone or with other standard treatments, in about 543 people with B-cell non-Hodgkin lymphoma. The goal is to find the best dose and see how well it shrinks tumors. Participants receive active treatment; no one ge…

This study tests a new oral drug called ARQ 531 (nemtabrutinib) in about 190 people with certain blood cancers (like lymphoma or leukemia) that have returned or not responded to prior therapy. The goal is to find the safest dose and see if the drug can shrink tumors. Participants…

This study tests whether combining two drugs, obinutuzumab and CC-99282, can control follicular lymphoma that has a high tumor burden and has not been treated before. About 33 adults with stage II–IV disease will receive the combination and be monitored for side effects and respo…

This early-phase study tests a new type of immunotherapy called tri-specific CAR T-cells for people with B-cell lymphomas that have come back or not responded to treatment. The therapy is designed to target three different markers on cancer cells to improve effectiveness and redu…

This study aims to create a more accurate tool to predict whether follicular lymphoma patients will remain free of cancer progression two years after their first treatment. Researchers are combining clinical information with molecular data from 370 patients to build and test this…